Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of May 2019. The document serves as a transaction notification regarding a specific insider transaction rather than a comprehensive financial report.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The only financial data present relates to a specific share transaction:
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Transaction Price: £10.13 per share.
- Volume: 533 shares.
Material Changes
The filing reports an acquisition of 533 ordinary shares by Mr. P Thomson, President of Global Affairs. This transaction occurred on May 17, 2019, on the London Stock Exchange following the exercise of options granted on October 29, 2015, under the Company's ShareSave Plan. No other material changes to the company's financial position are disclosed in this document.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is strictly a regulatory notification of a director's share purchase.
Important Facts for Investors to Verify
- Verify the total number of shares held by Mr. P Thomson post-transaction to assess overall insider ownership levels.
- Confirm the current market price of GSK ordinary shares relative to the £10.13 exercise price to understand the immediate economic gain.
- Review the full terms of the ShareSave Plan referenced to understand vesting schedules and future potential exercises.